Morgan Stanley: ASCO 2026 China Biotechnology Conference Highlights

Overview

Morgan Stanley's ASCO 2026 China Biotechnology Conference Highlights report analyzes recent developments in lung cancer treatments WuKong28 and Optitrop-Lung05. The report notes WuKong28 demonstrates consistent efficacy in international Phase III trials matching domestic data, showing strong global translational potential. Optitrop-Lung05 shows promising preliminary efficacy but requires further safety validation. Additionally, experts express caution regarding ADC use in first-line treatment, emphasizing the need to balance efficacy and toxicity.

Core views

Morgan Stanley's ASCO 2026 analysis focuses on two lung cancer treatments: WuKong28 and Optitrop-Lung05. WuKong28 demonstrates consistent efficacy in international Phase III trials matching domestic data, with experts noting its global translational potential. Optitrop-Lung05 shows promising preliminary efficacy but requires further safety validation. Experts also caution that ADC use in first-line treatment requires careful consideration due to potential toxicity impacts on patient quality of life, and is only suitable for specific patient populations. Additionally, VEGF-targeted therapy may offer greater benefits for Asian patients, consistent with historical data.

Analysis framework

Morgan Stanley evaluated WuKong28 and Optitrop-Lung05 efficacy and safety through analysis of oral presentations at ASCO 2026. The report primarily relies on clinical trial data and expert opinions, incorporating global and Asian market data comparisons to assess potential market applications. The analysis also considers risk-benefit profiles of different treatment approaches to provide investors with comprehensive insights.

Methodology notes

• Industry/Industrial Analysis FrameworkSupply-demand framework

  Supply-Demand Framework

  Assesses market potential and competitive landscape by analyzing drug demand and supply dynamics.

• Industry/Industrial Analysis FrameworkVolume-price decomposition

  Volume-Price Decomposition

  Evaluates market performance and profitability by analyzing sales volume and price changes.

• Industry/Industrial Analysis FrameworkPenetration Rate S-Curve

  Penetration Rate S-Curve

  Assesses growth potential and market acceptance by analyzing changes in drug market penetration rates.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuKong28

  WuKong28 demonstrates consistent efficacy in international Phase III trials matching domestic data, showing strong global translational potential.

  Strengths

  Consistent efficacy matching domestic data with strong global translational potential.

  Weaknesses

  Lower brain metastasis rate requiring further validation.

  Comparison

  Lower brain metastasis rate compared to CHRYSALIS study.

  Risks

  Requires further validation of safety and long-term efficacy.

• Optitrop-Lung05

  Optitrop-Lung05 shows promising preliminary efficacy but requires further safety validation.

  Strengths

  Promising preliminary efficacy data.

  Weaknesses

  Safety profile requires further validation.

  Comparison

  Superior efficacy compared to control group.

  Risks

  Safety validation required, potentially impacting patient quality of life.

Key data

• WuKong28 Brain Metastasis RateApproximately 12%Lower than 20%+ in CHRYSALIS study, attributed to strict patient selection.
• Optitrop-Lung05 Brain Metastasis Rate~LSD%Data unavailable, requires further validation.

Impact & implications

Morgan Stanley believes WuKong28 has significant global translational potential that could positively impact the lung cancer treatment market. Optitrop-Lung05's preliminary data shows promising efficacy but requires further safety validation. Experts recommend cautious use of ADCs in first-line treatment due to potential toxicity impacts on patient quality of life. Additionally, VEGF-targeted therapy may offer greater benefits for Asian patients, consistent with historical data.

Risks

• WuKong28's global translational potential requires further validation.
• Optitrop-Lung05's safety profile requires further validation.
• ADC use in first-line treatment requires caution due to potential impacts on patient quality of life.

What to watch

• WuKong28's global translational potential.
• Optitrop-Lung05's safety validation progress.
• Risks associated with ADC use in first-line treatment.